Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR plus or Quadruple Negative Disease

被引：100

作者：

Barton, Valerie N. ^{[1
]}

D'Amato, Nicholas C. ^{[1
]}

Gordon, Michael A. ^{[1
]}

Christenson, Jessica L. ^{[1
]}

Elias, Anthony ^{[1
]}

Richer, Jennifer K. ^{[1
]}

机构：

[1] Univ Colorado, Dept Pathol, Aurora, CO 80015 USA

来源：

HORMONES & CANCER | 2015年 / 6卷 / 5-6期

基金：

美国国家卫生研究院;

关键词：

EXTERNAL QUALITY-ASSURANCE; PROSTATE-CANCER; SPLICE VARIANT; MOLECULAR SUBTYPES; EXPRESSION; IDENTIFICATION; GROWTH; ENZALUTAMIDE; TRASTUZUMAB; PROGRESSION;

D O I：

10.1007/s12672-015-0232-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype that lacks estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) amplification. Due to the absence of these receptors, TNBC does not respond to traditional endocrine or HER2-targeted therapies that improve patient prognosis in other breast cancer subtypes. TNBC has a poor prognosis, and currently, there are no effective targeted therapies. Some TNBC tumors express androgen receptor (AR) and may benefit from AR-targeted therapies. Here, we review the literature on AR in TNBC and propose that TNBC be further sub-classified as either AR+ TNBC or quadruple negative breast cancer since targeting AR may represent a viable therapeutic option for a subset of TNBC.

引用

页码：206 / 213

页数：8

共 63 条

[1]

Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression [J].